Pharmacologically evoked apnoeas. Receptors and nervous pathways involved

Małgorzata Szereda-Przestaszewska1, Katarzyna Kaczyńska1

  • 1Department of Respiration Physiology, Mossakowski Medical Research Centre Polish Academy of Sciences, A. Pawińskiego 5, 02-106 Warsaw, Poland.

Life Sciences
|December 17, 2018
PubMed

Insights

This review examines how substances activating vagal afferents cause transient apnoeic spells. It highlights the role of 5-HT1A serotonin receptors in reversing opioid-induced respiratory depression.

Area of Science:

  • Neuroscience
  • Respiratory Physiology
  • Pharmacology

Background:

  • Transient apnoeic spells can be triggered by chemical stimulation of vagal afferents.
  • Understanding the neural circuits and receptors involved is crucial for managing respiratory dysfunction.

Purpose of the Study:

  • To review the incidence of transient apnoeic spells induced by substances activating vagal chemically sensitive afferents.
  • To explore the role of specific receptors and pontomedullary circuits in respiratory cessation.
  • To investigate the potential of 5-HT1A serotonin receptors in counteracting opioid-induced respiratory inhibition.

Main Methods:

  • Literature review of studies on vagal afferent stimulation and respiratory control.
  • Analysis of research on pontomedullary respiratory circuits.
  • Examination of receptor specificity and expression, particularly 5-HT1A receptors.

Main Results:

  • Substances activating vagal chemically sensitive afferents can induce transient apnoeic spells.
  • Pontomedullary circuits play a key role in the cessation of respiration.
  • 5-HT1A serotonin receptors demonstrate an excitatory drive that can overcome opioid-induced respiratory inhibition.

Conclusions:

  • Vagal afferent activation is a significant factor in transient apnoeic spells.
  • Targeting 5-HT1A serotonin receptors offers a potential therapeutic strategy for opioid-induced respiratory depression.

Related Concept Videos

What is a Nervous System?01:25

What is a Nervous System?

Overview
104.7K
Insulin: The Receptor and Signaling Pathways01:28

Insulin: The Receptor and Signaling Pathways

Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
3.2K
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers01:22

Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers

α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
1.6K
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
1.7K
The Parasympathetic Nervous System01:14

The Parasympathetic Nervous System

Overview
115.4K
The Sympathetic Nervous System01:25

The Sympathetic Nervous System

Overview
103.5K